Use of CTLA4Ig for induction of mixed chimerism and renal allograft tolerance in nonhuman primates

American Journal of Transplantation

Volumn 14, Issue 12, 2014, Pages 2704-2712

  Yamada, Y ^a   Ochiai, T ^a   Boskovic, S ^a   Nadazdin, O ^a   Oura, T ^a   Schoenfeld, D ^b   Cappetta, K ^a   Smith, R N ^b   Colvin, R B ^b   Madsen, J C ^a   Sachs, D H ^b   Benichou, G ^a   Cosimi, A B ^a   Kawai, T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Basic (laboratory) research science; bone marrow hematopoietic stem cell transplantation; kidney transplantation nephrology; tolerance: chimerism; tolerance: costimulation blockade; tolerance: experimental

Indexed keywords

ABATACEPT; BELATACEPT; CYCLOSPORIN; THYMOCYTE ANTIBODY; ANTIBODY CONJUGATE; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CHIMERA; DRUG USE; ENZYME LINKED IMMUNOSPOT ASSAY; GLOMERULOPATHY; GRAFT RECIPIENT; GRAFT SURVIVAL; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY GRAFT REJECTION; LONG TERM SURVIVAL; MACACA FASCICULARIS; MEMORY CELL; MIXED LYMPHOCYTE REACTION; NATURAL KILLER T CELL; NONHUMAN; REGULATORY T LYMPHOCYTE; THYMUS; WHOLE BODY RADIATION; ALLOTRANSPLANTATION; ANIMAL; BONE MARROW TRANSPLANTATION; DONOR; FLOW CYTOMETRY; GRAFT REJECTION; HISTOCOMPATIBILITY; IMMUNOLOGY; KIDNEY DISEASES; KIDNEY FUNCTION TEST; KIDNEY TRANSPLANTATION; TRANSPLANTATION TOLERANCE;

ANIMALS; ANTIBODIES, MONOCLONAL; BONE MARROW TRANSPLANTATION; CHIMERISM; FLOW CYTOMETRY; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MACACA FASCICULARIS; TISSUE DONORS; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION TOLERANCE; TRANSPLANTATION, HOMOLOGOUS; WHOLE-BODY IRRADIATION;

EID: 84910612694     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12936     Document Type: Article

References (43)

1. Kawai T, Cosimi AB, Colvin RB, et al. Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation 1995; 59: 256-262.
2. Kawai T, Poncelet A, Sachs DH, et al. Long-term outcome and alloantibody production in a non-myeloablative regimen for induction of renal allograft tolerance. Transplantation 1999; 68: 1767-1775.
3. Kawai T, Sogawa H, Boskovic S, et al. CD154 blockade for induction of mixed chimerism and prolonged renal allograft survival in nonhuman primates. Am J Transplant 2004; 4: 1391-1398.
4. Yamada Y, Boskovic S, Aoyama A, et al. Overcoming memory T-cell responses for induction of delayed tolerance in nonhuman primates. Am J Transplant 2012; 12: 330-340.
5. Kawai T, Andrews D, Colvin RB, Sachs DH, Cosimi AB., Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med 2000; 6: 114.
6. Koyama I, Kawai T, Andrews D, et al. Thrombophilia associated with anti-CD154 monoclonal antibody treatment and its prophylaxis in nonhuman primates. Transplantation 2004; 77: 460-462.
7. Xu Y, Kolber-Simonds D, Hope JA, et al. The anti-CD2 monoclonal antibody BTI-322 generates unresponsiveness by activation-associated T cell depletion. Clin Exp Immunol 2004; 138: 476-483.
8. Kawai T, Cosimi AB, Spitzer TR, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008; 358: 353-361.
9. Kawai T, Sachs DH, Sykes M, Cosimi AB., HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2013; 368: 1850-1852.
10. Cosimi AB, Delmonico FL, Wright JK, et al. Prolonged survival of nonhuman primate renal allograft recipients treated only with anti-CD4 monoclonal antibody. Surgery 1990; 108: 406-413; discussion 413-414.
11. Nadazdin O, Boskovic S, Murakami T, et al. Phenotype, distribution and alloreactive properties of memory T cells from cynomolgus monkeys. Am J Transplant 2010; 10: 1375-1384.
12. Pitcher CJ, Hagen SI, Walker JM, et al. Development and homeostasis of T cell memory in rhesus macaque. J Immunol 2002; 168: 29-43.
13. Nadazdin O, Boskovic S, Murakami T, et al. Host alloreactive memory T cells influence tolerance to kidney allografts in nonhuman primates. Sci Transl Med 2011; 3: 86ra51.
14. Wekerle T, Sayegh MH, Ito H, et al. Anti-CD154 or CTLA4Ig obviates the need for thymic irradiation in a non-myeloablative conditioning regimen for the induction of mixed hematopoietic chimerism and tolerance. Transplantation 1999; 68: 1348-1355.
15. Kurtz J, Shaffer J, Lie A, Anosova N, Benichou G, Sykes M., Mechanisms of early peripheral CD4 T-cell tolerance induction by anti-CD154 monoclonal antibody and allogeneic bone marrow transplantation: Evidence for anergy and deletion but not regulatory cells. Blood 2004; 103: 4336-4343.
16. Wekerle T, Sayegh MH, Chandraker A, Swenson KG, Zhao Y, Sykes M., Role of peripheral clonal deletion in tolerance induction with bone marrow transplantation and costimulatory blockade. Transplant Proc 1999; 31: 680.
17. Zhu ZX, Fan LY, Wang Q., Simultaneous blockade of costimulatory signals CD28-CD80 and CD40-CD154 combined with monoclonal antibody against CD25 induced a stable chimerism and tolerance without graft-versus-host disease in rat. Eur Surg Res 2011; 46: 109-117.
18. Pree I, Bigenzahn S, Fuchs D, et al. CTLA4Ig promotes the induction of hematopoietic chimerism and tolerance independently of indoleamine-2,3-dioxygenase. Transplantation 2007; 83: 663-667.
19. Wekerle T, Kurtz J, Ito H, et al. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat Med 2000; 6: 464-469.
20. Tomita Y, Khan A, Sykes M., Role of intrathymic clonal deletion and peripheral anergy in transplantation tolerance induced by bone marrow transplantation in mice conditioned with a nonmyeloablative regimen. J Immunol 1994; 153: 1087-1098.
21. Kawai T, Sachs DH, Cosimi AB., Tolerance to vascularized organ allografts in large-animal models. Curr Opin Immunol 1999; 11: 516-520.
22. Linsley PS, Greene JL, Tan P, et al. Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. J Exp Med 1992; 176: 1595-1604.
23. Shiraishi T, Yasunami Y, Takehara M, Uede T, Kawahara K, Shirakusa T., Prevention of acute lung allograft rejection in rat by CTLA4Ig. Am J Transplant 2002; 2: 223-228.
24. Akalin E, Chandraker A, Russell ME, Turka LA, Hancock WW, Sayegh MH., CD28-B7 T cell costimulatory blockade by CTLA4Ig in the rat renal allograft model: Inhibition of cell-mediated and humoral immune responses in vivo. Transplantation 1996; 62: 1942-1945.
25. Lin H, Bolling SF, Linsley PS, et al. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J Exp Med 1993; 178: 1801-1806.
26. Mola EM, Balsa A, Martinez Taboada V, et al. Abatacept use in rheumatoid arthritis: Evidence review and recommendations. Rheumatol Clin 2013; 9: 5-17.
27. Kirk AD, Harlan DM, Armstrong NN, et al. CTLA4-Ig, anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA 1997; 94: 8789-8794.
28. Levisetti MG, Padrid PA, Szot GL, et al. Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation. J Immunol 1997; 159: 5187-5191.
29. Larsen CP, Pearson TC, Adams AB, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005; 5: 443-453.
30. Page A, Srinivasan S, Singh K, et al. CD40 blockade combines with CTLA4Ig and sirolimus to produce mixed chimerism in an MHC-defined rhesus macaque transplant model. Am J Transplant 2012; 12: 115-125.
31. Ramakrishnan SK, Page A, Farris AB, et al. Evidence for kidney rejection after combined bone marrow and renal transplantation despite ongoing whole-blood chimerism in rhesus macaques. Am J Transplant 2012; 12: 1755-1764.
32. Kimikawa M, Sachs DH, Colvin RB, Bartholomew A, Kawai T, Cosimi AB., Modifications of the conditioning regimen for achieving mixed chimerism and donor-specific tolerance in cynomolgus monkeys. Transplantation 1997; 64: 709-716.
33. Boskovic S, Kawai T, Smith RN, et al. Monitoring antidonor alloantibodies as a predictive assay for renal allograft tolerance/long-term observations in nonhuman primates. Transplantation 2006; 82: 819-825.
34. Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353: 770-781.
35. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10: 535-546.
36. Rostaing L, Vincenti F, Grinyo J, et al. Long-term belatacept exposure maintains efficacy and safety at 5 years: Results from the long-term extension of the BENEFIT study. Am J Transplant 2013; 13: 2875-2883.
37. Pestana JO, Grinyo JM, Vanrenterghem Y, et al. Three-year outcomes from BENEFIT-EXT: A phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant 2012; 12: 630-639.
38. Vincenti F, Tedesco Silva H, Busque S, et al. Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: Efficacy, renal function and safety at 1 year. Am J Transplant 2012; 12: 2446-2456.
39. Kirk AD, Guasch A, Xu H, et al. Renal transplantation using belatacept without maintenance steroids or calcineurin inhibitors. Am J Transplant 2014; 14: 1142-1151.
40. Pilat N, Baranyi U, Klaus C, et al. Treg-therapy allows mixed chimerism and transplantation tolerance without cytoreductive conditioning. Am J Transplant 2010; 10: 751-762.
41. Pilat N, Farkas AM, Mahr B, et al. T-regulatory cell treatment prevents chronic rejection of heart allografts in a murine mixed chimerism model. J Heart Lung Transplant 2014; 33: 429-437.
42. Chavez H, Beaudreuil S, Abbed K, et al. Absence of CD4CD25 regulatory T cell expansion in renal transplanted patients treated in vivo with Belatacept mediated CD28-CD80/86 blockade. Transpl Immunol 2007; 17: 243-248.
43. Poirier N, Blancho G, Vanhove B., Alternatives to calcineurin inhibition in renal transplantation: Belatacept, the first co-stimulation blocker. Immunotherapy 2010; 2: 625-636.